Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Signal Pharmaceuticals LLC (AKA: Signal Pharmaceuticals Inc)
Profile last edited on: 11/27/2023      CAGE: -----      UEI: ----------

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1993
First Award
1994
Latest Award
1999
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4550 Towne Centre Court
San Diego, CA 92121
   (858) 558-7500
   N/A
   www.signalpharm.com
Location: Single
Congr. District: 50
County: San Diego

Public Profile

Signal Pharmaceuticals now functions as a wholly-owned subsidiary of Celgene Corporation following the merger of the two firms in September 2000. The Signal Pharmaceuticals, LLC Corp. is identifying new classes of small molecule drugs that selectively regulate disease-associated genes through a corporate strategy that emphasizes (i) integrating advanced target-to-drug discovery technologies and (ii) leveraging drug targets and drug candidates across multiple therapeutic areas.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
3
Conversion Rate
60.00%
Phase I Dollars
$551,926
Phase II Dollars
$2,348,315
Total Awarded
$2,900,241

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1999 2 NIH $949,955
Project Title: Tools For Discovery Of Anti-Osteoporotic Drugs
1999 1 NIH $152,016
Project Title: Tools For Discovery Of Novel Cancer Therapeutics
1998 2 NIH $849,955
Project Title: Tools for Discovery of Novel Anti-Osteoporotic Drugs
1997 2 NIH $848,315
Project Title: Human Neurons in Vitro: Characterization of Receptors
1997 1 NIH $100,000
Project Title: Feasibility Study Of A Novel Hpv Antiviral Target

Key People / Management

  Alan J Lewis -- President

  Miguel S Barbosa

  Frank M Mercurio

  Dinah Sah

  Bernd Stein

Company News

There are no news available.